Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 85.33M에 달합니다.
과대 평가된
회사의 최신 PE은 4.57로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매수
최신 기관 보유 주식 수는 317.36M주이며, 전 분기 대비 0.24% 증가했습니다.
시장 활동 증가
회사는 투자자들의 관심이 높아져, 최근 20일간 회전율이 1.91입니다.